Highly Specialised Technologies (HSTs)
SCHARR-TAG has produced technology assessment reports since 2000. We are a dedicated team including experienced economic modellers, systematic reviewers, statisticians, information specialists and project managers.
Off
- 2024
- 2023
- 2022
- 2021
-
Odevixibat for progressive familial intrahepatic cholestasis [ID1570].
- 2019
-
Volanesorsen for treating familial chylomicronaemia syndrome [ID1326].
- 2018
-
Patisiran for treating hereditary transthyretin-related amyloidosis [ID1279].
Recombinant human alpha-mannosidase for treating alpha-mannosidosis [ID800].
- 2014
-
Atypical haemolytic uraemic syndrome (aHUS) - eculizumab [HST1] (ID703).